JENKINTOWN, Pa., May 2, 2024 /PRNewswire/ -- SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oral small-molecule biosynthetic compounds for the treatment of inflammatory diseases, today announced the appointment of Stefan C. Weiss, MD, MBA, as Chief Medical Officer.

宾夕法尼亚州詹金敦，2024年5月2日/PRNewswire/-SFA Therapeutics，Inc.，一家临床阶段的生物制药公司，开发用于治疗炎症性疾病的口服小分子生物合成化合物，今天宣布任命Stefan C.Weiss，MD，MBA为首席医官。

Dr. Weiss is a physician-scientist and entrepreneur with 25 years of experience in the healthcare and life sciences industries. Dr. Weiss leverages his clinical expertise and business acumen to lead teams through patient care and complex business and strategic implementations. A leader in the field of dermatology, Dr.

Weiss博士是一位医生、科学家和企业家，在医疗保健和生命科学行业拥有25年的经验。Weiss博士利用其临床专业知识和商业敏锐度，领导团队完成患者护理以及复杂的业务和战略实施。皮肤病学领域的领导者Dr。

Weiss is a practicing dermatologist who has secured multiple new drug approvals for the treatment of inflammatory skin diseases and has been selected by his peers as one of the nation's top doctors. Dr. Weiss has authored more than 100 peer-reviewed abstracts, posters, and manuscripts.   .

韦斯是一位执业皮肤科医生，已获得多项治疗炎症性皮肤病的新药批准，并被同行选为美国顶级医生之一。维斯博士撰写了100多篇同行评议的摘要、海报和手稿。。

'Dr. Weiss brings decades of multi-faceted clinical and industry experience in both dermatology and immunology,' commented Ira Spector, Ph.D., CEO of SFA Therapeutics. 'His expertise in dermatologic therapeutic development will be indispensable for the company as we advance SFA-002 in clinical trials for the treatment of psoriasis.

'博士。SFA Therapeutics首席执行官艾拉·斯佩克特（IraSpector）博士评论道，维斯（Weiss）在皮肤病学和免疫学方面带来了数十年的多方面临床和行业经验随着我们在治疗牛皮癣的临床试验中推进SFA-002，他在皮肤病治疗开发方面的专业知识将对公司不可或缺。

Dr. Weiss will also advise us on the best course of action for leveraging our platform to develop additional therapeutic candidates for other indications.'.

Weiss博士还将为我们提供最佳行动方案的建议，以利用我们的平台开发其他适应症的其他治疗候选药物。”。

'I am honored to join the SFA Therapeutics team to help shape the clinical pathway forward for SFA-002 and other candidates that target inflammatory disease. As a practicing dermatologist, I have witnessed the immense need for novel therapeutics with greater efficacy and fewer side effects than the currently available treatments for chronic inflammatory skin conditions,' stated Dr.

“我很荣幸加入SFA治疗团队，帮助塑造SFA-002和其他针对炎症性疾病的候选人的临床路径。作为一名执业皮肤科医生，我见证了与目前可用的慢性炎症性皮肤病治疗方法相比，对具有更高疗效和更少副作用的新型治疗方法的巨大需求。

Weiss, Chief Medical Officer of SFA Therapeutics. 'I am confident in SFA Therapeutics' novel approach which acts on multiple therapeutic pathways by using endogenous biosynthetic compounds. SFA Therapeutics is well-positioned to provide potentially safer and more efficacious treatments for chronic inflammatory diseases like psoriasis.'.

魏斯（Weiss）是SFA Therapeutics的首席医疗官我对SFA Therapeutics的新方法充满信心，该方法通过使用内源性生物合成化合物作用于多种治疗途径。SFA Therapeutics能够为牛皮癣等慢性炎症性疾病提供潜在的更安全和更有效的治疗方法。

Most recently, Dr. Weiss was the Managing Director of Dermatology at OM1, a company focused on health care data analytics and artificial intelligence. In this position, he was responsible for deepening OM1's clinical focus and expertise around Immunology. He provided guidance on the scientific standards and clinical relevance of real-world data offerings across immunologic diseases.

最近，Weiss博士担任OM1皮肤科董事总经理，OM1是一家专注于医疗保健数据分析和人工智能的公司。在这个职位上，他负责深化OM1在免疫学方面的临床重点和专业知识。他提供了关于免疫疾病中真实世界数据提供的科学标准和临床相关性的指导。

In addition, he oversaw the development of prospective studies to collect real-world evidence, including the ClinPro Derm™ Protocol..

此外，他监督了前瞻性研究的发展，以收集现实世界的证据，包括ClinPro-Derm™协议。。

Dr. Weiss received his undergraduate degree with honors from Yale University, his MD and MSc in clinical research from the Duke University School of Medicine, and his MBA from the Kellogg School of Management at Northwestern University. He completed a residency in Dermatology at Stanford University and a Fellowship in Bioethics at the National Institute of Health..

Weiss博士获得了耶鲁大学的荣誉学士学位，杜克大学医学院的临床研究医学博士和硕士学位，以及西北大学凯洛格管理学院的MBA学位。他在斯坦福大学（Stanford University）获得了皮肤病学住院医师学位，并在美国国立卫生研究院（National Institute of Health）获得了生物伦理学奖学金。。

About SFA Therapeutics

关于SFA Therapeutics

SFA Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing oral small-molecule biosynthetic compounds for the treatment of inflammatory diseases. Based on breakthrough research licensed from Temple University, SFA Therapeutics' platform has the potential to develop safer and more efficacious treatments for a number of chronic inflammatory diseases by uniquely tailoring the effects of patented formulations with target-specific adjuvants.

SFA Therapeutics，Inc.是一家临床阶段的生物制药公司，开发用于治疗炎症性疾病的口服小分子生物合成化合物。根据天普大学（Temple University）授权的突破性研究，SFA Therapeutics平台有可能通过独特地定制具有靶向特异性佐剂的专利制剂的作用，为许多慢性炎症性疾病开发更安全和更有效的治疗方法。

Its lead asset, SFA-002, is approaching Phase 2 clinical trials and has shown promising Phase 1a and Phase 1b results for the treatment of psoriasis. SFA Therapeutics has also received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to investigate SFA-001N in patients with metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), with or without fibrosis.

其主要资产SFA-002正在接近2期临床试验，并显示出治疗牛皮癣的有希望的1a期和1b期结果。美国食品和药物管理局（FDA）也批准了SFA Therapeutics的研究性新药（IND）申请，以研究代谢功能障碍相关脂肪性肝炎（MASH）患者的SFA-001N，也称为非酒精性脂肪性肝炎（NASH），有或没有纤维化。

SFA Therapeutics has an Orphan Disease Designation from the FDA for SFA-001 in the treatment of hepatocellular carcinoma, the most prevalent form of liver cancer..

SFA Therapeutics被FDA指定为SFA-001治疗肝细胞癌（最常见的肝癌形式）的孤儿疾病。。

SFA Therapeutics is headquartered in Jenkintown, Pennsylvania. Please visit www.sfatherapeutics.com to learn more.

SFA Therapeutics的总部位于宾夕法尼亚州的詹金敦。请访问www.sfatherapeutics.com了解更多信息。

Company Contact

公司联系人

Ira Spector, Ph.D.

Ira Spector博士。

SFA Therapeutics, Inc.

SFA治疗公司。

+1 267-584-1080

+1 267-584-1080

Media Contacts

媒体联系人

Tony Russo, Ph.D.

Tony Russo博士。

Russo Partners, LLC

Russo Partners，LLC

Tony@RussoPR.com

Tony@RussoPR.com

Maddie Stabinski

Maddie Stabinski

Russo Partners, LLC

Russo Partners，LLC

Madeline@RussoPR.com

Madeline@RussoPR.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/sfa-therapeutics-strengthens-management-team-with-appointment-of-chief-medical-officer-302132292.html

查看原始内容以下载多媒体：https://www.prnewswire.com/news-releases/sfa-therapeutics-strengthens-management-team-with-appointment-of-chief-medical-officer-302132292.html

SOURCE SFA Therapeutics, Inc.

来源：SFA Therapeutics，Inc。